Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

Mounjaro, manufactured by Lilly, may have emerged as the newest ... on other background drugs being administered as a standard of care. A trial can still be conducted without taking a patient ...

Access to Medicine Foundation report highlights barriers to insulin access for children with type 1 diabetes in low-income ...

Meanwhile, Eli Lilly’s Mounjaro and Zepbound have seen explosive ... In India, weight-loss drugs—particularly those repurposed from diabetes care—are strictly overseen by the Central Drugs ...

Eli Lilly is just weeks away from launching Mounjaro in the UK ... welcomed by patient organisation Diabetes UK, whose head of care, Douglas Twenefour, said: “Supporting people with type ...

Many videos on the social media platform TikTok that are focused on obsessive thoughts about food include patient ...

Mounjaro is an injectable medicine to manage type diabetes and lose weight. Know about Mounjaro hair loss, a potential side ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...